Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : KIO-301
Therapeutic Area : Genetic Disease
Study Phase : Phase I
Sponsor : Kiora Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : KIO-301 acts as a reversible 'photoswitch', specifically designed to restore the eyes' ability to perceive and interpret light in visually impaired patients with retinitis pigmentos.
Product Name : KIO-301
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 14, 2023
Lead Product(s) : KIO-301
Therapeutic Area : Genetic Disease
Highest Development Status : Phase I
Sponsor : Kiora Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
